Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

ACCC shares how a precision medicine steward—a dedicated navigator focused specifically on biopsy samples and biomarker testing processes and results—can make a daunting biomarker testing process incredibly efficient for cancer programs and practices everywhere.
Accelerated Approvals Reconsidered Blenrep (belantamab mafodotin-blmf) - GSK said Tuesday that following a request from FDA, it will withdraw its blood cancer drug from the U.S. market. The decision comes a little more than two years after the BCMA-directed antibody and microtubule inhibitor conjugate was granted an accelerated approval as 5th-line therapy for adult patients with relapsed …
ASSOCIATION OF COMMUNITY CANCER CENTERS PROVIDING EQUITABLE CARE TO PATIENTS WITH BLADDER CANCER Patients face many challenges and roadblocks on their treatment path, which can be exacerbated by social determinants of health and health disparities. Cancer care team members can take evidence-based steps to improve quality care and minimize disparities for patients with bladder cancer. Common …
ASSOCIATION OF COMMUNITY CANCER CENTERS Effective Practices in Bladder Cancer Care: MITIGATING DISPARITIES WITH GUIDELINE-BASED CARE Despite the expansion of therapeutic options for patients with bladder cancer (see Box 1), disparities per-sist in the United States (U.S.). Receipt of guideline- concordant treatment is suboptimal across the bladder cancer spectrum, especially for Black …
FIGURE 1. Cumulative Allowed Costs by Stage and Years Following Bladder Cancer Diagnosis ASSOCIATION OF COMMUNITY CANCER CENTERS Effective Practices in Bladder Cancer Care: ADDRESSING FINANCIAL BARRIERS TO QUALITY CARE Bladder cancer is well known to be one of the costliest cancers to treat. With advancements in treatment options (newer drugs and therapies), more costs are being shifted …
ASSOCIATION OF COMMUNITY CANCER CENTERS Effective Practices in Bladder Cancer Care: ENGAGING PATIENTS IN THEIR CARE Goals-of-Care Conversations As with all cancers, a bladder cancer diagnosis can be scary and overwhelming for both patients and their caregivers. Compared to other cancer types, however, patient experience of bladder cancer care is especially poor.1 For people with …
ASSOCIATION OF COMMUNITY CANCER CENTERS PROVIDING EQUITABLE CARE TO PATIENTS WITH BLADDER CANCER Patients face many challenges and roadblocks on their treatment path, which can be exacerbated by social determinants of health and health disparities. Cancer care team members can take evidence-based steps to improve quality care and minimize disparities for patients with bladder cancer. Common …
FIGURE 1. Cumulative Allowed Costs by Stage and Years Following Bladder Cancer Diagnosis ASSOCIATION OF COMMUNITY CANCER CENTERS Effective Practices in Bladder Cancer Care: ADDRESSING FINANCIAL BARRIERS TO QUALITY CARE Bladder cancer is well known to be one of the costliest cancers to treat. With advancements in treatment options (newer drugs and therapies), more costs are being shifted …
ASSOCIATION OF COMMUNITY CANCER CENTERS Effective Practices in Bladder Cancer Care: MULTISPECIALTY CLINICS Multidisciplinary care in the form of multispecialty bladder cancer clinics, has been shown to improve disease assessment and treatment recommendations for patients with bladder cancer, and increase patient access to specialty treatment and coordinated care.1,2 While insufficient clinic …
ASSOCIATION OF COMMUNITY CANCER CENTERS Effective Practices in Bladder Cancer Care: MULTISPECIALTY CLINICS Multidisciplinary care in the form of multispecialty bladder cancer clinics, has been shown to improve disease assessment and treatment recommendations for patients with bladder cancer, and increase patient access to specialty treatment and coordinated care.1,2 While insufficient clinic …
ASSOCIATION OF COMMUNITY CANCER CENTERS Effective Practices in Bladder Cancer Care: ENGAGING PATIENTS IN THEIR CARE Goals-of-Care Conversations As with all cancers, a bladder cancer diagnosis can be scary and overwhelming for both patients and their caregivers. Compared to other cancer types, however, patient experience of bladder cancer care is especially poor.1 For people with …
Accelerated Approvals Reconsidered Blenrep (belantamab mafodotin-blmf) - GSK said Tuesday that following a request from FDA, it will withdraw its blood cancer drug from the U.S. market. The decision comes a little more than two years after the BCMA-directed antibody and microtubule inhibitor conjugate was granted an accelerated approval as 5th-line therapy for adult patients with relapsed …
Accelerated Approvals Reconsidered Blenrep (belantamab mafodotin-blmf) - GSK said Tuesday that following a request from FDA, it will withdraw its blood cancer drug from the U.S. market. The decision comes a little more than two years after the BCMA-directed antibody and microtubule inhibitor conjugate was granted an accelerated approval as 5th-line therapy for adult patients with relapsed …
Accelerated Approvals Reconsidered Blenrep (belantamab mafodotin-blmf) - GSK said Tuesday that following a request from FDA, it will withdraw its blood cancer drug from the U.S. market. The decision comes a little more than two years after the BCMA-directed antibody and microtubule inhibitor conjugate was granted an accelerated approval as 5th-line therapy for adult patients with relapsed …
December 13, 2022
Learn about the key policy changes finalized by the Centers for Medicare & Medicaid Services (CMS) in the CY 2023 Medicare Physician Fee Schedule (PFS) and Hospital Outpatient Prospective Payment System (OPPS) final rules. Speakers will discuss how these reimbursement changes will impact oncology programs and practices starting January 1, 2023, and identify other legislative and regulatory updates …
PowerPoint Presentation Dec. 8, 2022 TxSCO Update Overview: Notable Updates 2 Federal • Prior Auth Proposed Rule • Lame Duck Expectations • Provider Cuts • HHS’ Policy Agenda for 2023 • Notable Reports • ASCO report on Prior Auth • Hospital Acquisitions Outside of Commuting Zones on the Rise State • Leadership Update • House Speaker • …
Accelerated Approvals Reconsidered Blenrep (belantamab mafodotin-blmf) - GSK said Tuesday that following a request from FDA, it will withdraw its blood cancer drug from the U.S. market. The decision comes a little more than two years after the BCMA-directed antibody and microtubule inhibitor conjugate was granted an accelerated approval as 5th-line therapy for adult patients with relapsed …
The NCCN closed out 2022 with a patient advocacy summit focused on sexual orientation and gender identity, highlighting the barriers that can prevent LGBTQ+ patients with cancer, as well as survivors, from accessing high-quality, equitable care.
Accelerated Approvals Reconsidered Blenrep (belantamab mafodotin-blmf) - GSK said Tuesday that following a request from FDA, it will withdraw its blood cancer drug from the U.S. market. The decision comes a little more than two years after the BCMA-directed antibody and microtubule inhibitor conjugate was granted an accelerated approval as 5th-line therapy for adult patients with relapsed …
Accelerated Approvals Reconsidered Blenrep (belantamab mafodotin-blmf) - GSK said Tuesday that following a request from FDA, it will withdraw its blood cancer drug from the U.S. market. The decision comes a little more than two years after the BCMA-directed antibody and microtubule inhibitor conjugate was granted an accelerated approval as 5th-line therapy for adult patients with relapsed …